Armed with new data from its development partner Bharat Biotech, Ocugen is planning to press ... according to a preprint posted on the MedRxiv website, where studies can be published before ...

On Friday, Ocugen Inc (OCGN) stock saw a modest uptick, ending the day at $0.71 which represents no change from the prior close of of $0.71. The stock opened at $0.72 and touched a low of $0.7 during ...

Ocugen, Inc. has announced the commencement of its Phase 1 clinical trial for OCU200, targeting diabetic macular edema (DME). The trial, which has begun dosing its first patient, aims to evaluate ...

On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...

Ocugen, Inc. (NASDAQ:OCGN) reported its Q3 2024 earnings, showcasing notable advancements in its clinical programs. Despite a drop in its stock price during regular trading hours, the aftermarket ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...

Ocugen, Inc. (NASDAQ:OCGN) reported its Q3 2024 earnings, showcasing notable advancements in its clinical programs. Despite a drop in its stock price during regular trading hours, the aftermarket saw ...

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen (OCGN – Research Report), with a price target of $7.00. Discover outperforming stocks ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a ...